Obesity and diabetes are debilitating conditions affecting more than 1 billion patients worldwide; they are the most costly chronic conditions to healthcare systems surpassing cardiovascular diseases and cancer and their prevalence is increasing and impacting every corner of the globe.
Metabolic surgery remains the only sustainable solution to treat obesity and the resulting diabetes, but surgery is invasive, is associated with complexity, complications, and high costs. The new GLP-1 receptor agonists drugs can be effective but very costly, need to be taken long-term, leading to high burden on payors and patient non-compliance. As for the commercially available minimally invasive endoscopic solutions, although safe, are not effective.
BariaTek Medical is dedicated to the development of minimally invasive solutions with the goal to match the efficacy of surgery and surpass it in terms of safety, ease of use, reversibility, and economics.
The BariTon™ Device
BariaTek Medical’s first product, the BariTon™, is a soft, atraumatic, reversible implant that is delivered via an endoscope through the mouth in a few minutes in an outpatient setting. The BariTon™ is expected to be the first implant of its kind to mimic the multiple beneficial effects of metabolic surgery with no alteration to the patient’s anatomy therefore allowing for full reversibility.
Chief Executive Officer
Chief Medical Officer
Chief Financial Officer
Chief Business Officer
Head of V&V
Head of R&D
14 rue Jean Antoine de Baïf